Drug Profile
Research programme: progressive multifocal leukoencephalopathy therapies - Alnylam Pharmaceuticals/Biogen
Alternative Names: JC virus RNAi therapeutics - Alnylam Pharmaceuticals/Biogen; PML RNAi therapeutics - Alnylam Pharmaceuticals/BiogenLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Alnylam Pharmaceuticals; Biogen Idec
- Developer Alnylam Pharmaceuticals
- Class Small interfering RNA
- Mechanism of Action RNA interference; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Progressive multifocal leukoencephalopathy
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Progressive multifocal leukoencephalopathy in USA
- 01 Apr 2008 Pharmacodynamics data from a preclinical study in Progressive multifocal leukoencephalopathy released by Alnylam
- 07 Nov 2007 Pharmacodynamics data from a preclinical study in progressive multifocal leukencephalopathy presented at the 37th Annual Meeting of the Society for Neuroscience (SfN-2007)